Medtronic's Renal Denervation Breakthrough: A De-Risked Catalyst Poised for Growth

Related Articles

Is Medtronic Finally Poised for a Turnaround

8 months ago

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

7 months ago

Is EcoSolutions Waste Poised for a Biofuel Breakthrough

7 months ago

Is Medtronic's MiniMed Spin-Off a Smart Bet for Investors

7 months ago

Category

You may also like

Stock News•1 months ago

Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision

Mineralys Therapeutics was upgraded to Buy ahead of a December FDA decision on lorundrostat. The drug shows competitive efficacy and safety, with blockbuster revenue potential and possible label expan...

MLYS

Share

Stock News•2 months ago

Medtronic: The CAS Catalyst Can Close A 27% Peer Discount

Medtronic's CAS segment, now 5-6% of revenue and annualizing above $2B, could reach $3B in a few years, potentially closing a 27% peer discount. Guidance targets 6.75%-7.25% organic growth and $5.90-$...

MDT

Share

Stock News•3 months ago

Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study

Autonomix Medical showed its system can detect and confirm renal nerve activity changes in a preclinical study, supporting its physiology-guided renal denervation development.

AMIX

Share